Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza virus vaccine live intranasal (trivalent) - AstraZeneca

Drug Profile

Influenza virus vaccine live intranasal (trivalent) - AstraZeneca

Alternative Names: CAIV-T; Fluenz; FluMist; Influenza vaccine live intranasal; Trivalent live attenuated seasonal influenza vaccine - AstraZeneca

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Michigan
  • Developer AstraZeneca
  • Class Influenza virus vaccines live; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 02 Jul 2019 Influenza virus vaccine live intranasal is not yet available for Influenza virus infections (Prevention) in Liechtenstein, Iceland (Intranasal)
  • 30 Jun 2016 Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) recommends against the use of FluMist®
  • 01 Feb 2012 Launched for Influenza virus infections in United Kingdom (Intranasal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top